{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-016981","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.916275+00:00","generated_at":"2026-05-15T05:59:54.459295+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain","bullets":["Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.","Non-cash gain of $365.4M from fair value increase in GMP Bio JV investment, partially offset by $111.6M deferred tax provision.","JV subsidiaries Sapu Bio and Sapu Nano formalized; OT-101 Phase 1 combo trial completed and Phase 2/3 pancreatic cancer enrolling.","Deciparticle nanoparticle platform advancing six candidates; everolimus trial enrolling in Australia, INDs expected for palbociclib and docetaxel in 2026.","PDAOAI AI platform expanded to over 100,000 curated abstracts, contributing to seven peer-reviewed publications in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-016981","json":"https://secwatch.observer/filing/0001493152-26-016981.json","markdown":"https://secwatch.observer/filing/0001493152-26-016981.md","text":"https://secwatch.observer/filing/0001493152-26-016981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/0001493152-26-016981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315226016981/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T05:59:54.459295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}